Back to Search

A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in ≥2nd Line Small Cell Lung Cancer (SCLC) Treatment


  • Protocol Number: 202207103
  • Principal Investigator: Waqar, Saiama
  • Cancer Types: Lung

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions